Dr. Hiebert received his Ph.D. from Northwestern University studying the molecular biology of viruses that infect the upper respiratory track before pursuing postdoctoral studies at Duke University where he studied the cell cycle. He initiated his independent research laboratory at St. Jude Children’s Research Hospital studying the E2F family of transcription factors and their regulation by the retinoblastoma tumor suppressor. While at St. Jude, he started a research program in acute myeloid leukemia studying the t(8;21), which is one of the most frequent chromosomal translocations in acute myeloid leukemia.  He also studied the inv(16) in AML and the t(12;21) in childhood B cell acute leukemia.  In 1997 Dr. Hiebert moved to Vanderbilt University School of Medicine and in 2000 he was tapped to lead the Vanderbilt-Ingram Cancer Center’s Program in Signal Transduction and Cell Proliferation.  In 2008, Dr. Hiebert was named an Ingram Professor of Cancer Research and became the Associate Director for Basic Research in the cancer center, a position that he held until 2020.  In 2010 he also assumed the duties of Associate Director for Shared Resources and in 2020 he became Associate Director for Research Education. In 2013 he was named the Hortense B. Ingram Professor of Cancer Research. He has been continuously funded by National Cancer Institute for over 25 years, leads a National Cancer Institute funded training program for graduate students and postdoctoral fellows.  He has served as a reviewer for the National Cancer Institute, Leukemia and Lymphoma Society, and the American Cancer Society, and served on the American Cancer Society’s Council for Extramural Grants.  He currently serves on the National Cancer Advisory Board for the National Cancer Institute, where he is acting Chair. His research interests include hematopoietic stem cell functions, epigenetics, and the mechanism of action of epigenetic drugs, and he has authored over 150 manuscripts.